You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 6, 2025

Drug Price Trends for NDC 13811-0538


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 13811-0538

Drug Name NDC Price/Unit ($) Unit Date
FOLIVANE-F CAPSULE 13811-0538-90 0.28633 EACH 2025-01-22
FOLIVANE-F CAPSULE 13811-0538-90 0.29613 EACH 2024-12-18
FOLIVANE-F CAPSULE 13811-0538-90 0.28854 EACH 2024-11-20
FOLIVANE-F CAPSULE 13811-0538-90 0.31656 EACH 2024-10-23
FOLIVANE-F CAPSULE 13811-0538-90 0.31118 EACH 2024-09-18
FOLIVANE-F CAPSULE 13811-0538-90 0.31268 EACH 2024-08-21
FOLIVANE-F CAPSULE 13811-0538-90 0.32033 EACH 2024-07-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 13811-0538

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Drug NDC: 13811-0538

Introduction

When analyzing the market and price projections for a specific drug, such as the one identified by the National Drug Code (NDC) 13811-0538, it is crucial to consider several factors including the drug's classification, market trends, regulatory environment, and economic indicators.

Drug Classification and Details

The NDC 13811-0538 corresponds to a specific pharmaceutical product. However, the exact details of this NDC are not provided in the sources, so we will use a similar example (NDC 13811-708) to illustrate the key points.

  • Drug Type: For instance, NDC 13811-708 is for Methylphenidate Hydrochloride, an extended-release oral tablet classified as a Central Nervous System Stimulant[1].
  • Labeler and Marketing: The drug is labeled and distributed by Trigen Laboratories, LLC, and was approved under an Abbreviated New Drug Application (ANDA)[1].

Market Trends in Pharmaceutical Prices

General Price Increases

Pharmaceutical prices have been increasing over the years, posing significant challenges to affordability for patients, healthcare payers, employers, and taxpayers. From January 2022 to January 2023, more than 4,200 drug products experienced price increases, with 46% of these increases exceeding the rate of inflation. The average price increase during this period was 15.2%, translating to $590 per drug product[2].

Single Source vs. Multi-Source Drugs

Price increases vary between single-source and multi-source drugs. Single-source drugs, which are typically more expensive, had an average price increase of 7.4% ($958) from January 2022 to January 2023, while multi-source drugs saw an average increase of 26.0% ($69)[2].

Regulatory Environment

FDA Oversight and NDC Directory

The FDA maintains the National Drug Code Directory, which includes prescription drugs, over-the-counter (OTC) drugs, and insulin products. Each drug product is assigned a unique NDC, which identifies the labeler, product, and trade package size[5].

Approval Process

Drugs must undergo rigorous approval processes, including review of safety, effectiveness, and manufacturing practices. The FDA's approval process ensures that drugs meet stringent standards before they are marketed[5].

Economic Indicators and Projections

Overall Drug Price Inflation

For the period from January 1, 2025, to December 31, 2025, the projected overall drug price inflation rate is expected to be around 0%, according to the Vizient Pharmacy Market Outlook. However, this projection does not account for individual drug price fluctuations, which can be significant[4].

Impact of Advanced Therapies

The increasing cost of advanced therapies, such as gene therapies, is a significant factor in the pharmaceutical market. The recent approval of a $4.25 million gene therapy highlights the escalating costs and the need for sustainable financial models in healthcare[4].

Price Projections for NDC 13811-0538

Given the lack of specific data on NDC 13811-0538, we can infer potential price trends based on the broader market analysis:

  • General Trends: If the drug falls under the category of single-source or multi-source drugs, it may experience price increases similar to those observed in the market. For single-source drugs, an average increase of around 7-10% could be expected, while multi-source drugs might see higher percentage increases but lower absolute dollar amounts[2].

  • Regulatory and Economic Factors: The FDA's regulatory environment and economic indicators such as inflation rates and healthcare spending trends will influence the price projections. However, without specific data, it is challenging to predict exact price changes.

Future of Pharmaceutical Pricing

Role of AI and Health Tech

The pharmaceutical industry is expected to see significant changes with the adoption of artificial intelligence (AI) and health technology. AI will play a crucial role in drug discovery, clinical trial design, and real-time patient monitoring, which could impact pricing by reducing development costs and improving efficiency[3].

Personalized Medicine

The growth of personalized medicine, driven by AI and synthetic data, may lead to more targeted and effective treatments, potentially altering the pricing landscape by introducing new cost structures and reimbursement models[3].

Key Takeaways

  • Pharmaceutical prices are increasing, with significant variations between single-source and multi-source drugs.
  • Regulatory oversight by the FDA ensures that drugs meet safety and effectiveness standards.
  • Economic projections suggest a stable overall drug price inflation rate, but individual drugs can experience significant price changes.
  • The adoption of AI and health tech is expected to transform the pharmaceutical industry, potentially impacting pricing and efficiency.

FAQs

What is the National Drug Code (NDC) and how is it used?

The NDC is a unique, three-segment number that identifies a drug product, including the labeler, product, and trade package size. It is used to track and manage drug products in the pharmaceutical market[5].

How do price increases in pharmaceuticals compare to inflation rates?

From January 2022 to January 2023, 46% of drug price increases exceeded the rate of inflation, with an average increase of 15.2%[2].

What role is AI expected to play in the pharmaceutical industry in 2025?

AI is expected to be more widely adopted in clinical development, drug discovery, and real-time patient monitoring. It will also be used to train internal data science models and produce reports for decision-making[3].

How do gene therapies impact the pharmaceutical market?

Gene therapies are becoming more prevalent and are associated with high costs. The recent approval of a $4.25 million gene therapy highlights the need for sustainable financial models in healthcare[4].

What are the projected overall drug price inflation rates for 2025?

The projected overall drug price inflation rate for January 1, 2025, to December 31, 2025, is expected to be around 0% according to the Vizient Pharmacy Market Outlook[4].

Sources

  1. FDA Report: NDC 13811-708 Oral Tablet, Extended Release Methylphenidate Hydrochloride.
  2. ASPE Brief: Changes in the List Prices of Prescription Drugs, 2017-2023.
  3. Intelligencia AI Blog: 2025 Pharma Predictions: AI, Health Tech, and Data Trends to Watch.
  4. Vizient Inc.: Pharmacy Market Outlook Summer 2024.
  5. FDA: National Drug Code Database Background Information.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.